Format

Send to

Choose Destination
Curr Opin Pharmacol. 2006 Aug;6(4):369-75. Epub 2006 Jun 14.

Histone deacetylase inhibitors: gathering pace.

Author information

1
Topo Target, 87A Milton Park, Abingdon, Oxford OX14 4RY, UK.

Abstract

Reversible histone acetylation is one of the key mechanisms involved in the epigenetic control of gene expression. A variety of recent studies has revealed a role for acetylation in a much broader repertoire of physiological processes, including proliferation control and protein folding, and has highlighted how a variety of non-histone regulatory proteins are influenced by acetylation. Inhibition of histone deacetylase (HDAC) prompts tumour cells to enter apoptosis and, as a consequence, several HDAC inhibitors have entered clinical trials. It is likely that HDAC inhibitor drugs will provide an important class of new mechanism-based therapeutics for cancer.

PMID:
16781195
DOI:
10.1016/j.coph.2006.03.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center